Abstract Recent discoveries in the field of biomarkers for screening and early detection of ovarian cancer (OC) identified current needs for biomarkers capable of recognizing preclinical disease. The suggested approaches are (1) development of highly analytically sensitive CA 125 assays capable of detecting CA 125 released from small cancerous and preneoplastic lesions; (2) identification of biomarkers effective in CA 125–negative cases; and (3) performing biomarker discovery in samples obtained from patients with prophylactic bilateral salpingo-oophorectomy with pathologically confirmed preneoplastic lesions, or in appropriate animal models of ovarian cancer.
- Ovarian cancer
- CA 125
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The author declares that there are no conflicts of interest.